What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). This equivalency enables electronic methods while ensuring authenticity, integrity, availability, and non-repudiation through controls like validation (§11.10(a)), audit trails (§11.10(e)), access limitation (§11.10(d)), and electronic signature requirements (§§11.50–11.300).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or relied upon for regulated activities. This includes pharmaceutical, biotech, medical device, and CRO/CMO firms where electronic records replace paper for FDA-required records (e.g., batch records under 21 CFR 211), electronic submissions accepted per docket 92S-0251, or legally binding electronic signatures (§11.1(b)).

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)), with systems and documentation readily available for FDA review. FDA's 2003 guidance emphasizes risk-based approaches without mandating certifications.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; they must occur periodically via change control, risk reassessment, and operational reviews to maintain fitness for use. Integrate into quality systems with triggers like system changes, periodic reviews (§11.10(k)), or inspections, using risk-based validation lifecycles per FDA's 2003 guidance.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, recalls, and fines tied to predicate rule violations. Even with enforcement discretion on some elements (e.g., audit trails), failures in enforced controls like access (§11.10(d)) or signatures (§11.100) lead to data integrity issues, as seen in warning letters.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 controls can be mapped to frameworks like EU Annex 11 for computerized systems, focusing on shared principles of data integrity, audit trails, and electronic signatures. However, Part 11's narrow scope and enforcement discretion (§11.1(b)) require tailored alignment without direct equivalency.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Document scope decisions in SOPs per FDA's 2003 guidance, classifying systems as closed (§11.3(b)(4)) or open (§11.3(b)(9)) to prioritize controls.

What is the primary objective of ISO 19600?

ISO 19600 provides guidelines for establishing, developing, implementing, evaluating, maintaining, and improving an effective compliance management system (CMS). Published in 2014 as a principles-based, scalable framework, it applies to all organization types and sizes, emphasizing proportionality to structure, nature, and complexity. The standard uses a Plan-Do-Check-Act (PDCA) cycle with high-level structure, focusing on principles of good governance, transparency, and sustainability to embed compliance obligations—laws, regulations, voluntary codes—into culture, leadership, and operations.

Who is legally or professionally required to comply with ISO 19600?

No organization is legally required to comply with ISO 19600, as it provides non-mandatory guidelines rather than requirements. It targets any public, private, or non-profit entity seeking a structured CMS, scalable by size and complexity. Professionals such as CCOs, governance officers, and risk managers use it voluntarily for benchmarking, internal audits, and demonstrating good practices to regulators, courts, or stakeholders, particularly where courts consider CMS evidence in penalty determinations.

Does ISO 19600 require an external audit or third-party certification?

ISO 19600 does not require external audits or third-party certification, being a guidance standard without mandatory requirements. Organizations may conduct internal audits at planned intervals per Clause 9.2, using ISO 19011 for systematic, independent processes. Alignment is self-assessed; certification applies to its successor, ISO 37301.

How often should an assessment for ISO 19600 be performed?

ISO 19600 recommends ongoing monitoring, measurement, analysis, evaluation, and reassessment of compliance risks and obligations when changes or issues occur. Clause 9.1 requires continual monitoring plans with schedules; Clause 4.6 mandates risk reassessment on changes. Audits occur at planned intervals (Clause 9.2), and management reviews (Clause 9.3) are periodic, considering performance data, audits, and nonconformities.

What are the consequences of non-compliance with ISO 19600?

There are no direct consequences for non-compliance with ISO 19600, as it imposes no legal requirements. Indirectly, weak CMS alignment may increase exposure to regulatory penalties, fines, or judicial scrutiny from unmet obligations, as courts may reference CMS effectiveness in sentencing. It serves as a governance benchmark for demonstrating due diligence.

Can ISO 19600 be mapped to other international frameworks?

Yes, ISO 19600 can be mapped to other international frameworks due to its high-level structure and PDCA alignment. Its clauses (context, leadership, planning, support, operation, evaluation, improvement) facilitate integration with management systems like quality or risk frameworks, preserving compliance independence while reducing silos.

What is the first step to begin implementing ISO 19600?

The first step is determining the CMS scope and organizational context per Clause 4.1–4.3. Document boundaries, internal/external issues, interested parties' needs, and compliance obligations (Clause 4.5), making the scope available as documented information. This establishes proportionality and governance principles like compliance function independence.

Standards Comparison

FDA 21 CFR Part 11 vs ISO 19600

FDA 21 CFR Part 11

Mandatory

1997

US FDA regulation for trustworthy electronic records and signatures

ISO 19600

Voluntary

2014

International guidelines for compliance management systems

Quick Verdict

FDA 21 CFR Part 11 mandates controls for trustworthy electronic records in life sciences, while ISO 19600 provides voluntary CMS guidelines for all organizations. Pharma firms adopt Part 11 for FDA compliance; others use ISO 19600 for risk-based governance.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

12-18 months

Key Features

Establishes equivalency of electronic records to paper records
Mandates secure, time-stamped audit trails for changes
Requires system validation for accuracy and integrity
Differentiates controls for closed versus open systems
Enforces unique electronic signatures with non-repudiation

Compliance Management

ISO 19600

ISO 19600:2014 Compliance management systems — Guidelines

Cost

€€€

Complexity

Medium

Implementation Time

6-12 months

Key Features

Principles of good governance for CMS independence
Risk-based compliance obligations identification
PDCA cycle with high-level structure integration
Proportionality to organization size and complexity
Focus on compliance culture and tone at top

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate rule records. The risk-based approach, clarified in 2003 guidance, narrows scope to relied-upon electronic records while enforcing core controls.

Key Components

Subpart B: Controls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits.
Subpart C: Electronic signature requirements (§§11.100-11.300) for uniqueness, manifestation, linking.
Core principles: authenticity, integrity, non-repudiation; no certification, but compliance via validation and SOPs.

Why Organizations Use It

Mandated for life sciences firms relying on electronic records; mitigates enforcement risks like warning letters; enhances data integrity, inspection readiness, efficiency; builds stakeholder trust in regulated operations.

Implementation Overview

Risk-based CSV with phases: scoping, validation (IQ/OQ/PQ), SOPs, training; for pharma/devices in U.S.; ongoing audits, no external certification.

ISO 19600 Details

What It Is

ISO 19600:2014, Compliance management systems — Guidelines, is an international standard providing non-certifiable guidance for establishing, implementing, evaluating, maintaining, and improving a Compliance Management System (CMS). It applies to all organization types and sizes, using a risk-based, scalable approach based on PDCA (Plan-Do-Check-Act) and high-level structure for integration with other ISO standards.

Key Components

Core clauses: context, leadership, planning, support, operation, performance evaluation, improvement.
Principles: good governance, proportionality, transparency, sustainability.
Emphasizes compliance obligations identification, risk assessment, controls, culture, and continual improvement.
No fixed controls; flexible, proportionate practices.

Why Organizations Use It

Mitigates compliance risks, reduces penalties, enhances governance.
Builds trust with regulators, stakeholders; supports judicial penalty mitigation.
Enables integration for efficiency; strategic enabler for market access.
Fosters ethical culture, operational resilience.

Implementation Overview

Phased: gap analysis, policy design, controls rollout, monitoring.
Scalable to size/complexity; voluntary alignment, no certification.
Universal applicability; withdrawn 2021, succeeded by certifiable ISO 37301.

Key Differences

Aspect	FDA 21 CFR Part 11	ISO 19600
Scope	Electronic records/signatures trustworthiness	Compliance management systems guidelines
Industry	FDA-regulated life sciences, pharma, devices	All organizations, any sector worldwide
Nature	Mandatory US FDA regulation	Voluntary international guidelines (withdrawn)
Testing	System validation, audit trails, inspections	Internal audits, management reviews, monitoring
Penalties	Warning letters, enforcement, product holds	No legal penalties, self-improvement focus

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

ISO 19600

Compliance management systems guidelines

Industry

FDA 21 CFR Part 11

FDA-regulated life sciences, pharma, devices

ISO 19600

All organizations, any sector worldwide

Nature

FDA 21 CFR Part 11

Mandatory US FDA regulation

ISO 19600

Voluntary international guidelines (withdrawn)

Testing

FDA 21 CFR Part 11

System validation, audit trails, inspections

ISO 19600

Internal audits, management reviews, monitoring

Penalties

FDA 21 CFR Part 11

Warning letters, enforcement, product holds

ISO 19600

No legal penalties, self-improvement focus

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and ISO 19600

FDA 21 CFR Part 11 FAQ

ISO 19600 FAQ

You Might also be Interested in These Articles...

Beyond Reactive: Transforming Compliance into Real-Time Threat Prevention

Discover how modern compliance monitoring tools leverage continuous, real-time oversight and automated alerts to shift organizations from reactive problem-solving to proactive threat detection and prevention, safeguarding against emerging risks before they escalate.

Proving CIS Controls v8.1 Works: A KPI & Evidence Framework for Board Reporting, Audits, and Continuous Assurance

Prove CIS Controls v8.1 effectiveness with KPI catalog, evidence checklist & reporting cadence. Ideal for board reports, audits & cyber-insurance. Measure outco

What if the EU would not have made GDPR mandatory...

Explore a world without mandatory GDPR: How would organizations manage data? What data privacy regs would emerge? Uncover impacts on businesses and privacy laws

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and ISO 19600 compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other ISO 19600 Comparisons

What It Is

Key Components

Subpart B: Controls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits.

Subpart C: Electronic signature requirements (§§11.100-11.300) for uniqueness, manifestation, linking.

Core principles: authenticity, integrity, non-repudiation; no certification, but compliance via validation and SOPs.

What It Is

Key Components

Core clauses: context, leadership, planning, support, operation, performance evaluation, improvement.

Principles: good governance, proportionality, transparency, sustainability.

Emphasizes compliance obligations identification, risk assessment, controls, culture, and continual improvement.

No fixed controls; flexible, proportionate practices.

Aspect

FDA 21 CFR Part 11

ISO 19600

Scope

Electronic records/signatures trustworthiness

Compliance management systems guidelines

Industry

FDA-regulated life sciences, pharma, devices

All organizations, any sector worldwide

Nature

Mandatory US FDA regulation

Voluntary international guidelines (withdrawn)

Testing

System validation, audit trails, inspections

Internal audits, management reviews, monitoring

Penalties

Warning letters, enforcement, product holds

No legal penalties, self-improvement focus